Abstract
The human colorectal tumor cell line HCT 116 was resistant to the cytotoxic effects of 5-fluorodeoxyuridine (FdUrd). The response to FdUrd was increased only slightly by the presence of 10 μM folinic acid (CF). HCT 116 formed FdUMP and CH2H4PteGlu polyglutamates after exposure to FdUrd and CF. The sensitivity to FdUrd correlated well with the extent of TS inhibition. The role of TS in the resistance of the cells to FdUrd was examined. HCT 116 expresses two TS enzymes, which differ in pI. The more basic TS has been detected in only HCT 116 cells. The other TS is identical in pI to the enzymes detected in other human cells. The variant TS differs from the common by His replacement of Tyr at residue 33. The variant TS exhibited a 3-fold lower affinity for FdUMP than the common TS. The enzymes co-expressed in HCT 116 exhibited an FdUMP binding constant similar to that of the variant TS. TS-deficient cells were transfected with cDNAs encoding the two TS polypeptides. Transfectants expressing the variant TS were more resistant to FdUrd cytotoxicity than cells expressing the common TS. Thus, the structural variation in TS reduced enzyme affinity for FdUMP and conferred resistance to FdUrd.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Mini, E., Trave, F., Rustum, Y.M., and Bertino, J.R. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmac. Ther. 47: 1–19 (1990).
Jenh, C.-H., Geyer, P.K., and Johnson, L.F. Control of thymidylate synthase mRNA content and gene transcription in an overproducing mouse cell line. Mol. Cell. Biol. 5: 2527–2532 (1985).
Chu, E., Koeller, D.M., Casey, J.L., Drake, J.C., Chabner, B.A., Elwood, P.C., Zinn, S., and Allegra, C.J. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc. Natl. Acad. Sci. USA 88: 8977–8981 (1991).
Washtien, W.L. Thymidylate synthetase levels as a factor in 5-fluorodeoxyuridine and methotrexate cytotoxicity in gastrointestinal tumor cells. Mol. Pharmacol. 21: 723–238 (1982).
Berger, S.H. and Berger, F.G. Thymidylate synthase as a determinant of 5-fluoro-2′-deoxyuridine response in human colonic tumor cell lines. Mol. Pharmacol. 34: 474–479 (1988).
Spears, C.P., Gustavsson, B.G., Berne, M., Frosing, R., Bernstein, L., and Hayes, A.A. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res. 48: 5894–5900 (1988).
Peters, G.J., van Groeningen, C.J., van der Wilt, C.L., Meijer, S., Smid, K., Laurensse, E., and Pinedo, H.M. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin. Sem. Oncol. 19: 26–35 (1992).
Berger, S.H., Jenh, C.-H., Johnson, L.F., and Berger, F.G. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol. Pharmacol. 28: 461–467 (1985).
Berger, S.H., Barbour, K.W., and Berger, F.G. A naturally occurring variation in thymidylate synthase is associated with a reduced response to 5-fluoro-2′-deoxyuridine in a human colon tumor cell line. Mol. Pharmacol. 34: 480–484 (1988).
Clark, J.L., Berger, S.H., Mittleman, A., and Berger, F.G. Thymidylate synthase gene amplification n a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat. Rep. 71: 261–265 (1987).
Bapat, A.R., Zarow, C., and Danenberg, P.V. Human leukemic cells resistant to 5-fluoro-2′-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides. J. Biol. Chem. 258: 4130–4136 (1983).
Jastreboff, M.M., Kedzierska, B., and Rode, W. Altered thymidylate synthetase in 5-fluorodeoxyuridine-resistant Ehrlich ascites carcinoma cells. Biochem. Pharmacol. 32: 2259–2267 (1983).
Danenberg, P.V. and Bapat, A.R. Thymidylate synthases isolated from human colon tumors have varied affinity towards 5-fluoro-2′-deoxyuridylate. Reg. Cancer Treat. 2: 1–4 (1989).
Barbour, K.W., Berger, S.H., and Berger, F.G. Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase. Mol. Pharmacol. 37: 515–518 (1990).
Davis, S.T. and Berger, S.H. Modulation of 5-fluoro-2′-deoxyuridine response by folinic acid in human colonic tumor cell lines: the role of thymidylate synthase. Mol. Pharmacol. 35: 422–427 (1989).
Nussbaum, R.L., Walmsley, R.M., Lesko, J.G., Airhart, S.D., and Ledbetter, D.H. Thymidylate synthase-deficient Chinese hamster cells: a selection system for human chromosome 18 and experimental system for the study of thymidylate synthase regulation and fragile X expression. Am. J. Hum. Genet. 37: 1192–1205 (1985).
Barbour, K.W., Hoganson, D.K., Berger, S.H., and Berger, F.G. A naturally-occurring tyrosine histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2′-deoxyuridine in mammalian and bacterial cells. Mol. Pharmacol. 42: 242–248 (1992).
Moran, R.G., Spears, C.P., and Heidelberger, C. Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridylate, 2′-deoxyuridylate, and thymidylate synthetase. Proc. Natl. Acad. Sci. USA 76: 1456–1460 (1979).
Dolnick, B.J. and Cheng, Y.-C. Human thymidylate synthetase derived from blast cells of patients with acute myelocytic leukemia. J. Biol. Chem. 252: 7697–7703 (1977).
Radparvar, S., Houghton, P.J., and Houghton, J.A. Characteristics of thymidylate synthase purified from a human adenocarcinoma. Arch. Biochem. Biophys. 260: 342–350 (1988).
Banerjee, C.K., Bennett, L.L., Jr., Brockman, R.W., Sani, B.P., and Temple, C., Jr. A convenient procedure for purification of thymidylate synthase from L1210 cells. Anal. Biochem. 72: 248–254 (1982).
Spears, C.P., Shahinian, A.H., Moran, R.G., Heidelberger, C., and Corbett, T.H. In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and — resistant murine colon adenocarcinomas. Cancer Res. 42: 450–456 (1982).
Lockshin, A. and Danenberg, P.V. Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem. Pharmacol. 30: 247–257 (1981).
Scatchard, G. The attractions of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 51: 660–672 (1940).
Yalowich, J.C. and Kaiman, T.I. Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemic cells in vitro. Biochem. Pharmacol. 34: 2319–2324 (1985).
Berger, S.H., Davis, S.T., Barbour, K.W., and Berger, F.G. The role of thymidylate synthase in the response to fluoropyrimidine-folinic acid conbinations. Adv. Exptl. Med. Biol. 244: 59–69 (1988).
Berger, S.H. Biochemical factors which influence the action of 5-fluoropyrimidines on thymidylate synthetase. Ph.D. Thesis, State University of New York at Buffalo (1982).
Evans, R.M., Laskin, J.D., and Hakala, M.T. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res. 41: 3288–3295 (1981).
Priest, D.G. and Mangum, M. Relative affinity of 5, 10-methylenetetrahydro-folylpolyglutamates for the Lactobacillus casei thymidylate synthetase-5-fluorodeoxyuridylate binary complex. Arch. Biochem. Biophys. 210: 118–123 (1981).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hughey, C.T., Barbour, K.W., Berger, F.G., Berger, S.H. (1993). Genetic Variation in Thymidylate Synthase Confers Resistance to 5-Fluorodeoxyuridine. In: Rustum, Y.M. (eds) Novel Approaches to Selective Treatments of Human Solid Tumors. Advances in Experimental Medicine and Biology, vol 339. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2488-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2488-5_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6060-5
Online ISBN: 978-1-4615-2488-5
eBook Packages: Springer Book Archive